Carol Amato, William Robinson and colleagues show that Nf-KB signaling may show which melanomas are “hot” enough to respond to immunotherapy Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for...

In 1960, scientists described the “Philadelphia chromosome” that causes chronic myeloid leukemia, and in 2001 the Food and Drug Administration approved the drug imatinib to disable the action of this cancer-causing genetic change. It was the dawn of...

Think of the protein BH3 like a finger that turns off a cancer cell survival switch. The problem is that most cancer cells have found ways to remove this “finger” – commonly, by breaking the action of a gene called p53 that puts the BH3 finger in motion. Now think of...

Immunotherapies use the immune system to fight cancer. But cancers like melanoma have found ways to turn off the immune system, allowing them to resist treatments and often leading to recurrence. Now University of Colorado Cancer Center clinical trial results...

Doctors often treat melanoma with drugs that unblind the immune system to cancer. And brain metastases associated with melanoma are often treated with precisely targeted radiation known as radiosurgery. Now a University of Colorado Cancer Center study published in the...